Del Mar

Del Mar Pharmaceuticals was a clinical-stage biopharmaceutical company focused on developing and commercializing new cancer therapies for patients with solid tumors who have failed standard-of-care treatments. The company's lead candidate, VAL-083 (dianhydrogalactitol), is a first-in-class DNA-targeting agent with a unique mechanism of action designed to overcome chemoresistance in glioblastoma multiforme (GBM). VAL-083 was evaluated in multiple clinical trials, including a pivotal Phase 3 study for recurrent GBM. In 2020, the company completed a strategic merger with Adhera Therapeutics to form Kintara Therapeutics, consolidating their oncology pipelines.